Salesforce, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Salesforce, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Jan 31, 2017 | $2.29B | Mar 6, 2017 |
| FY2017 | Oct 31, 2016 | $2.14B | Mar 6, 2017 |
| FY2017 | Jul 31, 2016 | $2.04B | Mar 6, 2017 |
| FY2017 | Apr 30, 2016 | $1.92B | Mar 6, 2017 |
| FY2017 | Jan 31, 2016 | $1.81B | Mar 6, 2017 |
| FY2017 | Oct 31, 2015 | $1.71B | Mar 6, 2017 |
| FY2017 | Jul 31, 2015 | $1.63B | Mar 6, 2017 |
| FY2017 | Apr 30, 2015 | $1.51B | Mar 6, 2017 |
| FY2016 | Jan 31, 2015 | $1.44B | Mar 7, 2016 |
| FY2016 | Oct 31, 2014 | $1.38B | Mar 7, 2016 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 31, 2026 | $41.53B | Mar 2, 2026 |
| FY2025 | Jan 31, 2025 | $37.90B | Mar 2, 2026 |
| FY2025 | Jan 31, 2024 | $34.86B | Mar 2, 2026 |
| FY2025 | Jan 31, 2023 | $31.35B | Mar 5, 2025 |
| FY2024 | Jan 31, 2022 | $26.49B | Mar 6, 2024 |
| FY2023 | Jan 31, 2021 | $21.25B | Mar 8, 2023 |
| FY2020 | Jan 31, 2020 | $4.85B | Mar 5, 2020 |
| FY2020 | Oct 31, 2019 | $4.51B | Mar 5, 2020 |
| FY2020 | Jul 31, 2019 | $4.00B | Mar 5, 2020 |
| FY2020 | Apr 30, 2019 | $3.74B | Mar 5, 2020 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 31, 2026 | $32.26B | Mar 2, 2026 |
| FY2025 | Jan 31, 2025 | $29.25B | Mar 2, 2026 |
| FY2025 | Jan 31, 2024 | $26.32B | Mar 2, 2026 |
| FY2025 | Jan 31, 2023 | $22.99B | Mar 5, 2025 |
| FY2024 | Jan 31, 2022 | $19.47B | Mar 6, 2024 |
| FY2023 | Jan 31, 2021 | $15.81B | Mar 8, 2023 |
| FY2020 | Jan 31, 2020 | $3.63B | Mar 5, 2020 |
| FY2020 | Oct 31, 2019 | $3.38B | Mar 5, 2020 |
| FY2020 | Jul 31, 2019 | $3.03B | Mar 5, 2020 |
| FY2020 | Apr 30, 2019 | $2.82B | Mar 5, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 31, 2026 | $7.46B | Mar 2, 2026 |
| FY2025 | Jan 31, 2025 | $6.20B | Mar 2, 2026 |
| FY2025 | Jan 31, 2024 | $4.14B | Mar 2, 2026 |
| FY2025 | Jan 31, 2023 | $208.00M | Mar 5, 2025 |
| FY2024 | Jan 31, 2022 | $1.44B | Mar 6, 2024 |
| FY2023 | Jan 31, 2021 | $4.07B | Mar 8, 2023 |
| FY2020 | Jan 31, 2020 | ($248.00M) | Mar 5, 2020 |
| FY2020 | Oct 31, 2019 | ($109.00M) | Mar 5, 2020 |
| FY2020 | Jul 31, 2019 | $91.00M | Mar 5, 2020 |
| FY2020 | Apr 30, 2019 | $392.00M | Mar 5, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 31, 2026 | $8.33B | Mar 2, 2026 |
| FY2025 | Jan 31, 2025 | $7.21B | Mar 2, 2026 |
| FY2025 | Jan 31, 2024 | $5.01B | Mar 2, 2026 |
| FY2025 | Jan 31, 2023 | $1.03B | Mar 5, 2025 |
| FY2024 | Jan 31, 2022 | $548.00M | Mar 6, 2024 |
| FY2023 | Jan 31, 2021 | $455.00M | Mar 8, 2023 |
| FY2020 | Jan 31, 2020 | ($36.00M) | Mar 5, 2020 |
| FY2020 | Oct 31, 2019 | $65.00M | Mar 5, 2020 |
| FY2020 | Jul 31, 2019 | $58.00M | Mar 5, 2020 |
| FY2020 | Apr 30, 2019 | $210.00M | Mar 5, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 31, 2026 | $5.99B | Mar 2, 2026 |
| FY2025 | Jan 31, 2025 | $5.49B | Mar 2, 2026 |
| FY2025 | Jan 31, 2024 | $4.91B | Mar 2, 2026 |
| FY2025 | Jan 31, 2023 | $5.06B | Mar 5, 2025 |
| FY2024 | Jan 31, 2022 | $4.47B | Mar 6, 2024 |
| FY2023 | Jan 31, 2021 | $3.60B | Mar 8, 2023 |
| FY2022 | Jan 31, 2020 | $2.77B | Mar 11, 2022 |
| FY2021 | Jan 31, 2019 | $1.89B | Mar 17, 2021 |
| FY2020 | Jan 31, 2018 | $1.55B | Mar 5, 2020 |
| FY2019 | Jan 31, 2017 | $1.21B | Mar 8, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 31, 2026 | $15.00B | Mar 2, 2026 |
| FY2025 | Jan 31, 2025 | $13.09B | Mar 2, 2026 |
| FY2025 | Jan 31, 2024 | $10.23B | Mar 2, 2026 |
| FY2025 | Jan 31, 2023 | $7.11B | Mar 5, 2025 |
| FY2024 | Jan 31, 2022 | $6.00B | Mar 6, 2024 |
| FY2023 | Jan 31, 2021 | $4.80B | Mar 8, 2023 |
| FY2022 | Jan 31, 2020 | $4.33B | Mar 11, 2022 |
| FY2021 | Jan 31, 2019 | $3.40B | Mar 17, 2021 |
| FY2020 | Jan 31, 2018 | $2.74B | Mar 5, 2020 |
| FY2019 | Jan 31, 2017 | $2.16B | Mar 8, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 31, 2026 | $594.00M | Mar 2, 2026 |
| FY2025 | Jan 31, 2025 | $658.00M | Mar 2, 2026 |
| FY2025 | Jan 31, 2024 | $736.00M | Mar 2, 2026 |
| FY2025 | Jan 31, 2023 | $798.00M | Mar 5, 2025 |
| FY2024 | Jan 31, 2022 | $717.00M | Mar 6, 2024 |
| FY2023 | Jan 31, 2021 | $710.00M | Mar 8, 2023 |
| FY2022 | Jan 31, 2020 | $643.00M | Mar 11, 2022 |
| FY2021 | Jan 31, 2019 | $595.00M | Mar 17, 2021 |
| FY2020 | Jan 31, 2018 | $534.00M | Mar 5, 2020 |
| FY2019 | Jan 31, 2017 | $464.00M | Mar 8, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 31, 2026 | $112.31B | Mar 2, 2026 |
| FY2025 | Jan 31, 2025 | $102.93B | Mar 2, 2026 |
| FY2025 | Jan 31, 2024 | $99.82B | Mar 5, 2025 |
| FY2024 | Jan 31, 2023 | $98.85B | Mar 6, 2024 |
| FY2023 | Jan 31, 2022 | $95.21B | Mar 8, 2023 |
| FY2022 | Jan 31, 2021 | $66.30B | Mar 11, 2022 |
| FY2021 | Jan 31, 2020 | $55.13B | Mar 17, 2021 |
| FY2020 | Jan 31, 2019 | $30.74B | Mar 5, 2020 |
| FY2019 | Jan 31, 2018 | $21.98B | Mar 8, 2019 |
| FY2018 | Jan 31, 2017 | $17.58B | Mar 9, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 31, 2026 | $53.16B | Mar 2, 2026 |
| FY2025 | Jan 31, 2025 | $41.76B | Mar 2, 2026 |
| FY2025 | Jan 31, 2024 | $40.18B | Mar 5, 2025 |
| FY2024 | Jan 31, 2023 | $40.49B | Mar 6, 2024 |
| FY2023 | Jan 31, 2022 | $37.08B | Mar 8, 2023 |
| FY2022 | Jan 31, 2021 | $24.81B | Mar 11, 2022 |
| FY2021 | Jan 31, 2020 | $21.24B | Mar 17, 2021 |
| FY2020 | Jan 31, 2019 | $15.13B | Mar 5, 2020 |
| FY2019 | Jan 31, 2018 | $11.61B | Mar 8, 2019 |
| FY2018 | Jan 31, 2017 | $10.08B | Mar 9, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 31, 2026 | $59.14B | Mar 2, 2026 |
| FY2025 | Jan 31, 2025 | $61.17B | Mar 2, 2026 |
| FY2025 | Jan 31, 2024 | $59.65B | Mar 2, 2026 |
| FY2025 | Jan 31, 2023 | $58.36B | Mar 2, 2026 |
| FY2025 | Jan 31, 2022 | $58.13B | Mar 5, 2025 |
| FY2024 | Jan 31, 2021 | $41.49B | Mar 6, 2024 |
| FY2023 | Jan 31, 2020 | $33.89B | Mar 8, 2023 |
| FY2022 | Jan 31, 2019 | $15.61B | Mar 11, 2022 |
| FY2021 | Jan 31, 2018 | $10.38B | Mar 17, 2021 |
| FY2020 | Jan 31, 2017 | $8.23B | Mar 5, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 31, 2026 | $57.94B | Mar 2, 2026 |
| FY2025 | Jan 31, 2025 | $51.28B | Mar 2, 2026 |
| FY2025 | Jan 31, 2024 | $48.62B | Mar 2, 2026 |
| FY2025 | Jan 31, 2023 | $48.57B | Mar 5, 2025 |
| FY2024 | Jan 31, 2022 | $47.94B | Mar 6, 2024 |
| FY2023 | Jan 31, 2021 | $26.32B | Mar 8, 2023 |
| FY2022 | Jan 31, 2020 | $25.13B | Mar 11, 2022 |
| FY2021 | Jan 31, 2019 | $12.85B | Mar 17, 2021 |
| FY2020 | Jan 31, 2018 | $7.31B | Mar 5, 2020 |
| FY2019 | Jan 31, 2017 | $7.26B | Mar 8, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 31, 2026 | $22.22B | Mar 2, 2026 |
| FY2025 | Jan 31, 2025 | $16.37B | Mar 2, 2026 |
| FY2025 | Jan 31, 2024 | $11.72B | Mar 5, 2025 |
| FY2024 | Jan 31, 2023 | $7.59B | Mar 6, 2024 |
| FY2023 | Jan 31, 2022 | $7.38B | Mar 8, 2023 |
| FY2022 | Jan 31, 2021 | $5.93B | Mar 11, 2022 |
| FY2021 | Jan 31, 2020 | $1.86B | Mar 17, 2021 |
| FY2020 | Jan 31, 2019 | $1.74B | Mar 5, 2020 |
| FY2019 | Jan 31, 2018 | $635.00M | Mar 8, 2019 |
| FY2018 | Jan 31, 2017 | ($464.91M) | Mar 9, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 31, 2026 | $7.33B | Mar 2, 2026 |
| FY2025 | Jan 31, 2025 | $8.85B | Mar 2, 2026 |
| FY2025 | Jan 31, 2024 | $8.47B | Mar 5, 2025 |
| FY2024 | Jan 31, 2023 | $7.02B | Mar 6, 2024 |
| FY2023 | Jan 31, 2022 | $5.46B | Mar 8, 2023 |
| FY2022 | Jan 31, 2021 | $6.20B | Mar 11, 2022 |
| FY2021 | Jan 31, 2020 | $4.15B | Mar 17, 2021 |
| FY2020 | Jan 31, 2019 | $2.67B | Mar 5, 2020 |
| FY2019 | Jan 31, 2018 | $2.54B | Mar 8, 2019 |
| FY2019 | Jan 31, 2017 | $1.61B | Mar 8, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 31, 2026 | $14.44B | Mar 2, 2026 |
| FY2025 | Jan 31, 2025 | $8.43B | Mar 2, 2026 |
| FY2025 | Jan 31, 2024 | $9.43B | Mar 5, 2025 |
| FY2024 | Jan 31, 2023 | $10.60B | Mar 6, 2024 |
| FY2023 | Jan 31, 2022 | $10.60B | Mar 8, 2023 |
| FY2022 | Jan 31, 2021 | $2.68B | Mar 11, 2022 |
| FY2020 | Jan 31, 2020 | $2.69B | Mar 5, 2020 |
| FY2019 | Jan 31, 2019 | $3.20B | Mar 8, 2019 |
| FY2018 | Jan 31, 2018 | $1.73B | Mar 9, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 31, 2026 | 7 | Mar 2, 2026 |
| FY2025 | Jan 31, 2025 | 6 | Mar 2, 2026 |
| FY2025 | Jan 31, 2024 | 4 | Mar 2, 2026 |
| FY2025 | Jan 31, 2023 | 0 | Mar 5, 2025 |
| FY2024 | Jan 31, 2022 | 1 | Mar 6, 2024 |
| FY2023 | Jan 31, 2021 | 4 | Mar 8, 2023 |
| FY2020 | Jan 31, 2020 | 0 | Mar 5, 2020 |
| FY2020 | Oct 31, 2019 | 0 | Mar 5, 2020 |
| FY2020 | Jul 31, 2019 | 0 | Mar 5, 2020 |
| FY2020 | Apr 30, 2019 | 0 | Mar 5, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 31, 2026 | 7 | Mar 2, 2026 |
| FY2025 | Jan 31, 2025 | 6 | Mar 2, 2026 |
| FY2025 | Jan 31, 2024 | 4 | Mar 2, 2026 |
| FY2025 | Jan 31, 2023 | 0 | Mar 5, 2025 |
| FY2024 | Jan 31, 2022 | 1 | Mar 6, 2024 |
| FY2023 | Jan 31, 2021 | 4 | Mar 8, 2023 |
| FY2020 | Jan 31, 2020 | 0 | Mar 5, 2020 |
| FY2020 | Oct 31, 2019 | 0 | Mar 5, 2020 |
| FY2020 | Jul 31, 2019 | 0 | Mar 5, 2020 |
| FY2020 | Apr 30, 2019 | 0 | Mar 5, 2020 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 31, 2026 | 929.00M | Mar 2, 2026 |
| FY2025 | Jan 31, 2025 | 962.00M | Mar 2, 2026 |
| FY2025 | Jan 31, 2024 | 971.00M | Mar 5, 2025 |
| FY2024 | Jan 31, 2023 | 981.00M | Mar 6, 2024 |
| FY2023 | Jan 31, 2022 | 989.00M | Mar 8, 2023 |
| FY2022 | Jan 31, 2021 | 919.00M | Mar 11, 2022 |
| FY2021 | Jan 31, 2020 | 893.00M | Mar 17, 2021 |
| FY2020 | Jan 31, 2019 | 770.00M | Mar 5, 2020 |
| FY2019 | Jan 31, 2018 | 730.00M | Mar 8, 2019 |
| FY2018 | Jan 31, 2017 | 707.46M | Mar 9, 2018 |